Humacyte (HUMA) | Stock Overview & Key Data
Humacyte Performance Comparison
Stock Range
Today's Range
Low: $1.41
High: $1.46
on September 4, 2025
52 Week Range
Low: $1.15
High: $6.77
on April 8, 2025
on December 20, 2024
All-Time High: $17.45 on August 30, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$393.1M
EPS
-0.47
P/E Ratio (TTM)
-1.20
Forward P/E
-1.80
P/B Ratio
59.42
PEG Ratio
0.02
Div. Yield
N/A
ROE
282.33%
Beta
1.902
Debt to Equity
2,072.16
Financial Highlights
Profitability
Gross Margin
29.24%
Operating Margin
-9,876.08%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-50.18%
Return on Equity (TTM)
282.33%
EBITDA
$-103.9M
Net Income (TTM)
$-58.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.01
Quarterly Revenue Growth (YoY)
-41.78%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Humacyte HUMA | 393.08M Small-cap | -7.59% | -35.40% | -44.49% | -54.38% | -71.81% | -72.30% | -67.63% | -85.12% |
| Vertex VRTX | 102.81B Large-cap | 1.24% | -15.95% | -10.97% | -18.36% | -2.18% | -15.19% | 35.88% | 53.87% |
| Regeneron REGN | 61.25B Large-cap | -2.14% | -0.76% | 16.97% | -16.03% | -20.69% | -49.87% | -21.69% | 4.12% |
| Centessa CNTA | 1.98B Small-cap | -4.65% | -1.80% | 26.02% | -3.31% | -9.77% | 10.42% | 290.84% | -27.40% |
| Kymera Therapeutics KYMR | 1.96B Small-cap | 1.08% | -3.34% | -4.65% | 37.55% | 3.20% | -7.05% | 43.78% | 35.30% |
| Cg Oncology CGON | 1.91B Small-cap | 15.79% | 18.59% | 16.40% | 24.76% | 6.80% | -18.69% | -11.68% | -11.68% |
Ownership & Short Interest
Insider Ownership
19.74%
Institutional Ownership
36.37%
Shares Short
34M
Short Ratio
6.17
Short % of Shares Outstanding
24.82%
Average 10-Day Volume
4M
Average 90-Day Volume
5M
Warning: Undefined variable $nickname in /usr/local/lsws/wordpress/wp-content/themes/egnitech-devyara/templates/stock-overview.php on line 329
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HUMA's 52-week high and low?
- In the last 52 weeks, Humacyte reached a high of $6.77 (on December 20, 2024) and a low of $1.15 (on April 8, 2025).
- What is the market cap and P/E ratio for HUMA?
- Curious about Humacyte's size and valuation? Its market capitalization stands at 393.08M. When it comes to valuation, the P/E ratio (trailing twelve months) is -1.20, and the forward P/E (looking ahead) is -1.80.
- Does HUMA pay dividends? If so, what's the yield?
- As for dividends, Humacyte isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Humacyte's main competitors or similar companies to consider before investing?
When looking at Humacyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX102.81B Healthcare Biotechnology -15.19% 35.88% Regeneron
REGN61.25B Healthcare Biotechnology -49.87% -21.69% Centessa
CNTA1.98B Healthcare Biotechnology 10.42% 290.84% Kymera Therapeutics
KYMR1.96B Healthcare Biotechnology -7.05% 43.78% Cg Oncology
CGON1.91B Healthcare Biotechnology -18.69% -11.68% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Humacyte Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Humacyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 282.33%, the Debt to Equity ratio from the most recent quarter is 2,072.16, and its Gross Profit Margin stands at 29.24%.
- What is the recent revenue and earnings growth for HUMA?
- Looking at Humacyte's growth, its revenue over the trailing twelve months (TTM) was $818K. Compared to the same quarter last year (YoY), quarterly revenue grew by -41.78%, and quarterly earnings saw a YoY growth of N/A.
- How much of HUMA stock is held by insiders and institutions?
- Wondering who owns Humacyte stock? Company insiders (like executives and directors) hold about 19.74% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 36.37%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.